HEAD AND NECK SQUAMOUS CELL CANCER
Clinical trials for HEAD AND NECK SQUAMOUS CELL CANCER explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CANCER trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cancers: XB010 trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for any side effects. About 396 adults with…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 26, 2026 11:13 UTC
-
New drug EPI-326 enters first human tests for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New injection combo shows promise against head and neck cancer
Disease control Recruiting nowThis early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: VLP Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Smart CAR t cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CANCER
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC